Impact of CT-relevant Skeletal Muscle Parameters on Post-chemotherapy Survival in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

作者：Siying Zhang, Zhenping Wu, Guo Sa, Zhan Feng, Feng Chen · 发表于：Current Medical Imaging Formerly Current Medical Imaging Reviews · 年份：2025 · DOI：10.2174/0115734056356822250205174104 · 被引用次数：1 · 研究领域：Nutrition and Health in Aging、Frailty in Older Adults、Muscle Physiology and Disorders

PURPOSE: The study aimed to investigate the association of CT-relevant skeletal muscle parameters, such as sarcopenia and myosteatosis, with survival outcomes in patients receiving chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC). METHODS: In this retrospective analysis, patients who began chemotherapy for unresectable PDAC were included. Sarcopenia and myosteatosis were assessed on pretreatment CT at the L3 level by skeletal muscle index and mean muscle attenuation with predefined cutoff values. The Cox proportional hazards model was used to analyze the factors associated with progression-free survival (PFS) and overall survival (OS) RESULTS: A total of 150 patients were enrolled. Compared to patients without sarcopenia, patients with sarcopenia had significantly worse PFS (p=0.003) and OS (p<0.001). Patients with myosteatosis had significantly worse PFS (p=0.01) and OS (p=0.002) compared to those without myosteatosis. In multivariate analysis, after adjusting for age, sex, tumor size, location, treatment modality, smoking, drinking, underlying diseases, and partial laboratory tests, sarcopenia remained an independent predictor of PFS (p=0.006) and OS (p<0.001). Myosteatosis remained an independent predictor of OS (p=0.008), but not of PFS. CONCLUSION: Sarcopenia and myosteatosis are independent prognostic factors for patients with unresectable pancreatic ductal adenocarcinoma after chemotherapy.